Company 4 Enochian Biosciences Inc NASDAQ: E
Post# of 32974
(Total Views: 329)
Posted On: 02/24/2019 11:26:40 AM
Company 4
Enochian Biosciences Inc
NASDAQ: ENOB
Market Cap: $300M
Revenue: Nothing (OMG)
Announced approval on the Dec. 5 after market close so with 2 more days of OTC trading and then uplisted the following monday.
Enochian's common stock is expected to begin trading on the NASDAQ Capital Market on December 10, 2018 under the ticker symbol “ENOB.” The Company's common stock will continue to trade on the Over-the-Counter Bulletin Board under the ticker symbol “ENOB” until market close on December 7, 2018.
“We believe that the uplisting to NASDAQ will help attract institutional investors, broaden our shareholder base and enhance trading liquidity. We are excited about this milestone and look forward to progressing our gene-modified cell therapy platform to treat infectious disease and cancer patients," stated Eric Leire, MD, CEO.
Enochian Biosciences Announces Uplisting to Nasdaq Under Symbol “ENOB”
https://finance.yahoo.com/news/enochian-biosc...00100.html
Enochian Biosciences Inc
NASDAQ: ENOB
Market Cap: $300M
Revenue: Nothing (OMG)
Announced approval on the Dec. 5 after market close so with 2 more days of OTC trading and then uplisted the following monday.
Enochian's common stock is expected to begin trading on the NASDAQ Capital Market on December 10, 2018 under the ticker symbol “ENOB.” The Company's common stock will continue to trade on the Over-the-Counter Bulletin Board under the ticker symbol “ENOB” until market close on December 7, 2018.
“We believe that the uplisting to NASDAQ will help attract institutional investors, broaden our shareholder base and enhance trading liquidity. We are excited about this milestone and look forward to progressing our gene-modified cell therapy platform to treat infectious disease and cancer patients," stated Eric Leire, MD, CEO.
Enochian Biosciences Announces Uplisting to Nasdaq Under Symbol “ENOB”
https://finance.yahoo.com/news/enochian-biosc...00100.html
(6)
(0)